目的 探讨强肝胶囊联合复方二氯醋酸二异丙胺治疗慢性乙型肝炎的临床疗效。方法 回顾性分析2021年6月-2023年6月河南中医药大学第一附属医院消化内科收治的100例慢性乙型肝炎患者的临床资料,根据治疗方式不同将患者分为对照组和治疗组,每组各50例。对照组患者静脉滴注复方二氯醋酸二异丙胺注射液,40 mg/次,用0.9%氯化钠溶液100 mL稀释,1次/d。治疗组在对照组的治疗基础上口服强肝胶囊,3粒/次,3次/d。两组连续治疗30 d。观察两组的临床疗效和临床症状缓解时间,比较治疗前后两组肝功能指标和血清炎性因子水平的变化情况。结果 治疗后,治疗组总有效率是98.00%,显著高于对照组的82.00%(P<0.05)。治疗后,治疗组出现的乏力、腹胀、畏食、肝区疼痛缓解时间均短于对照组(P<0.05)。治疗后,两组总胆红素(TBil)、丙氨酸转氨酶(ALT)、天冬氨酸氨基转氨酶(AST)均较同组治疗前显著降低(P<0.05);治疗后,治疗组肝功能指标显著低于对照组(P<0.05)。治疗后,两组患者白细胞介素17(IL-17)、转化生长因子β1(TGF-β1)、基质金属蛋白酶组织抑制物-1(TIMP-1)水平均显著低于同组治疗前,而干扰素-γ(INF-γ)水平高于治疗前(P<0.05);治疗后,治疗组血清学指标改善优于对照组(P<0.05)。结论 强肝胶囊联合复方二氯醋酸二异丙胺治疗慢性乙型肝炎效果确切,能加快临床症状有效缓解,并促进肝功能有效好转,使机体局部炎性反应减弱,值得临床借鉴应用。

Objective To explore the clinical effect of Qianggan capsule combined with compound diisopropylamine dichloroacetate in treatment of chronic hepatitis B. Methods Clinical data of 100 patients with chronic hepatitis B admitted to the Department of Gastroenterology of the First Affiliated Hospital of Henan University of Chinese Medicine from June 2021 to June 2023 were retrospectively analyzed. The patients were divided into control group and treatment group according to different treatment methods, with 50 cases in each group. Patients in the control group were iv administered with Compound Diisopropylamine Dichloroacetate Injection, 40 mg/time, diluted with 0.9% sodium chloride solution 100 mL, once daily. Patients in the treatment group were po administered with Qianggan Capsules on the basis of the control group, 3 grains/time, 3 times daily. Both groups were treated continuously for 30 d. The clinical efficacy and duration of clinical symptom remission were observed, and the changes of liver function indexes and serum inflammatory factors before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 98.00%, which was significantly higher than that of the control group (82.00%, P < 0.05). After treatment, the time of fatigue, abdominal distension, fear of eating and relief of liver pain in the treatment group were shorter than those in the control group (P < 0.05). After treatment, total bilirubin (TBil), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in 2 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the liver function index of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the levels of interleukin17 (IL-17), transforming growth factor β1 (TGF-β1) and matrix metalloproteinase-1 (TIMP-1) in 2 groups were significantly lower than before treatment, while the levels of interferon-γ (INF-γ) were higher than before treatment (P < 0.05). After treatment, the improvement of serological indexes in treatment group was better than that in control group (P < 0.05). Conclusion Qianggan Capsule combined with compound diisopropylamine has accurate effect in treatment of chronic hepatitis B, and can accelerate the effective relief of clinical symptoms, promote the effective improvement of liver function, weaken the local inflammatory response of the body, which is worthy of clinical application.

R975